Originally presented in Science Translational Medicine, this article co-written with Merck & Co. presents a set of bifunctional HIV therapies, dubbed targeted activator of cell kill (TACK) molecules, that were optimized for simultaneous antiviral activity and selective elimination of infected CD4+ T cells from HIV-1 patients.
